ENLIVEX LTD
ENLVNASDAQ🏆 #5064 by market capEarnings Nov 12US Equity
$2.64▼ $0.09 (−3.30%)
Market closed · at closeTrack ENLV
Get earnings, price moves & breaking news on Telegram
24h▼ 3.3%
7d▼ 16.6%
14d▼ 27.2%
30d▼ 66.2%
ytd▼ 98.5%
1y▼ 98.9%
🏦Market Cap
$65M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.60 – $2.64
- 52-Week Range
- $2.22 – $434.40
- Volume (shares)
- 1,836
- Avg Volume (shares)
- —
- Shares Outstanding
- 24.5M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- 0.0
- P/S Ratio
- —
- EPS (TTM)
- $149.76
- Dividend Yield
- —
- Dilution (1yr)
- +120.1%
ENLIVEX LTD
ENLVFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▼ −3.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$10M▼ −20.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.2M▲ +120.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▼ −$1M YoY
StockOtter · stockotter.spaceAbout ENLIVEX LTD
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.